An experimental obesity pill being developed by Structure Therapeutics helped lower the blood sugar levels of people with Type 2 diabetes in a clinical trial, but didn’t match the degree of weight loss observed in testing of a rival medicine.
The results disclosed Monday show that Type 2 diabetics treated with Structure’s drug in a Phase 2 trial had a statistically significant 1% reduction in blood glucose after three months of treatment, compared to placebo recipients. No serious adverse events were reported among drug recipients and only one patient on Structure’s medicine dropping out of the trial. The majority of side effects were mild to moderate, according to the company.
